AAN-I-IFNs in patients with FVH and associated OR. (A) Luciferase-based neutralization assay to detect auto-Abs neutralizing 10 ng/ml IFN-α2, IFN-ω, or IFN-β. Samples with a RLA <15% are considered neutralizing. (B) Luciferase-based neutralization assay to detect auto-Abs neutralizing 100 pg/ml IFN-α2 or IFN-ω or 1 ng/ml IFN-β. (C) Proportion of type I IFNs neutralized in the patients, in individuals with HAV-HBV FVH and in individuals with HSV-FVH. (D) OR for the presence of AAN-I-IFNs in all individuals with FVH, relative to the general population, with adjustment for age by logistic regression. The horizontal bars indicate the upper and lower limits of the 95% CI. IFN-α, auto-Abs neutralizing IFN-α2 (regardless of their effects on other IFNs); IFN-ω, auto-Abs neutralizing IFN-ω (regardless of their effects on other IFNs); IFN-α ± ω ± β, auto-Abs neutralizing IFN-α2 and/or IFN-ω and/or IFN-β; IFN-α + ω, auto-Abs neutralizing both IFN-α2 and IFN-ω. (E) OR for the presence of AAN-I-IFNs in individuals with HSV-FVH vs. HAV/HBV-FVH.